The treatment of end-stage heart failure has evolved substantially with advances in medical
treatment, cardiac transplantation, and mechanical circulatory support (MCS) devices such …

The medical management of patients supported with durable continuous flow left ventricular
assist device (LVAD) support encompasses pharmacological therapies administered in the …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally used for diabetes mellitus,
are gaining more popularity for other indications, owing to their positive cardiovascular and …

Mechanical circulatory support is increasingly being used as bridge-to-transplant and
destination therapy in patients with advanced heart failure. Technologic improvements have …

Background The use of left ventricular assist devices (LVADs) for patients with end-stage
cardiac failure awaiting heart transplantation has become increasingly common. However …

Infection remains a common cause of morbidity and mortality in patients with both left
ventricular assist devices (LVADs) and cardiac implanted electronic devices (CIEDs) with …

The Aeson total artificial heart (A-TAH) has been developed for patients at risk of death from
biventricular failure. We aimed to assess the inflammatory status in nine subjects implanted …

Background The use of left ventricular assist devices (LVADs) for patients with end-stage
cardiac failure awaiting heart transplantation has become increasingly common. However …

Background Active bloodstream infection (BSI) is a contraindication for heart transplantation
(HT). However, some critical patients with BSI may undergo HT as a life‐saving procedure …

ABSTRACT Background Driveline infections (DLIs) at the exit site are frequent in patients
with left ventricular assist devices (LVADs). The dynamics from colonization to infection are …